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Abstract
Hepatitis C virus is a major cause of chronic liver diseases which can lead to permanent liver damage,
hepatocellular carcinoma and death. The presently available treatment with interferon plus ribavirin, has limited
benefits due to adverse side effects such as anemia, depression and “flu-like” symptoms. Needless to mention, the
effectiveness of interferon therapy is predominantly, if not exclusively, limited to virus type 3a and 3b whereas in
Europe and North America the majority of viral type is 1a and 2a. Due to the limited efficiency of current therapy,
RNA interference (RNAi) a novel regulatory and powerful silencing approach for molecular therapeutics through a
sequence-specific RNA degradation process represents an alternative option. Several reports have indicated the
efficiency and specificity of synthetic and vector based siRNAs inhibiting HCV replication. In the present review, we
focused that combination of siRNAs against virus and host genes will be a better option to treat HCV
Background
HCV infection is a serious global health problem that
affects 180 million people worldwide and 10 million
people in Pakistan [1]. Hepatitis C virus (HCV) causes
acute and chronic hepatitis which can eventually lead to
permanent liver damage, hepatocellular carcinoma and
death [2]. Of those acutely infected with HCV, around
85% develop chronic infection. Approximately 70% of
patients with chronic viremia develop chronic liver dis-
ease, 10-20% of which develop liver cirrhosis. It was
estimated by the World Health Organization in 2004
that the annual deaths due to liver cancer caused by
HCV and cirrhosis were 308,000 and 785,000, respec-
tively [3].
H C Vi sas m a l le n v e l o p e dv i r u sw i t hap o s i t i v es e n s e ,
single-stranded RNA genome that encodes a large
polyprotein of 3010 amino acids. The polyprotein is
co- and posttranslationally processed by cellular and
virally encoded proteases to produce four structural
(Core, E1, E2 and P7) and six non-structural (NS2,
NS3, NS4A, NS4B, NS5A, NS5B) proteins [4,5].
Among the structural protein, HCV envelop protein E1
and E2 are highly glycosylated and play an important
part in cell entry. HCV NS3 serine protease and NS5b
play an important role in replication. HCV NS3 serine
protease, NS5B RNA-dependent RNA polymerase and
HCV structural proteins are important targets for anti-
viral drug development.
There are six major and more than 80 subtypes of
HCV. This classification is based on nucleotide variation
among different HCV isolate. They occur in different
proportion in different parts of the world. Genotype 1a
and 1b are the most common genotypes in the United
States and Europe [6,7]. The most prevalent HCV geno-
type in Pakistan is 3a followed by 3b and 1a [8].
Presently, there is no vaccine available for prevention
of HCV infection due to high degree of strain variation.
Current therapeutic options for hepatitis C are limited,
especially for genotype 1. For genotypes 2 and 3, pegy-
lated interferon in combination with ribavirin, can
lead to a sustained virological response in up to 80% of
patients [9]. However, the therapy is expensive and
often associated with side effects that may lead to dis-
continuation of therapy [10]. Hemolytic anemia, cough,
shortness of breath & treatogenicity are the most com-
mon adverse effect associated with ribavirin treatment,
and muscle aches, fatigue & neuropsychiatric adverse
effects of IFN-a lead to premature cessation of therapy
in 10 to 20% of patients [11,12]. Moreover, cost of inter-
feron for 6 month treatment ranging from 50,000 to
150,000 is beyond the financial range of most patients.
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RNA interference (RNAi) is actually a sequence-speci-
fic RNA humiliation process in the cytoplasm of eukar-
yotic cells that is induced by double-stranded RNA
(dsRNA). This RNA silencing mechanism, which was
first described in Caenorhabditis elegans and Drosophila
melanogaster, also possesses many similarities with post-
transcriptional gene silencing in plants, and the process
of quelling in Neurospora crassa [13,14]. RNAi and
related RNA silencing mechanisms are supposed to act
as a natural defense against incoming viruses and the
expression of transposable elements [15]. Besides the
antiviral function of RNAi, there is evidence that RNAi
plays an important role in regulating cellular genes
expression. These features have characterized RNAi
both as an ancient and fundamentally important
mechanism in eukaryotic cell biology [16]. Sequence-
specific siRNA targeting of key human genes are ideal
for studying protein function in cells. To recognize
genes involved in a given cellular process, cell can be
transfected with different siRNA and assayed for differ-
ent response profiles.
Mechanism of Silencing
RNAi is exploits the conserved, powerful gene regula-
tion pathway, by which dsRNA molecules are used to
trigger the catalytic degradation of the targeted gene’s
mRNA, thereby effectively silencing its expression. The
underlying RNAi process can be briefly summarized as
follows: (Figure 1)
1. Firstly a “trigger"dsRNA is introduced into the
cell’s cytoplasm.
2. Second, is the generation of siRNA pool by the
Dicer enzyme (and associated co-factors), which pro-
cesses the trigger dsRNA and forms a pool of small
interfering RNAs (siRNAs); these are ~21 base pairs
in length, double stranded and include 2 nucleotide
overhangs at both 3’ ends.
3. Thridly, the processed siRNAs are then delivered
to an Argonaut-containing RNA-Induced Silencing
Complex (RISC), which unwinds the two siRNA
strands, retaining one strand to act as a RISC-target-
ing co-factor.
4. Fourthly, the siRNA-associated RISC bind to the
target mRNA, through the bound siRNA which con-
fers sequence-based specificity to the associated
RISC complex, allowing recognition and base-pairing
with the complementary target mRNA.
5. And lastely, RISC complex contains an endonu-
clease activity, which is attributed to the Argonaut
subunit, causes a single-site cleavage of the target
mRNA approximately in the middle of the siRNA
binding region. The resulting fragments of target
mRNA is thus destabilized and subsequently gets
fully degraded through natural endogenous mechan-
ism[17].
RNAi is a useful tactic in future Therapeutics
As whole human genome have been sequenced there is
need to develop significant tools understanding the
functions of specific genes, for this reason the need for
a tool like siRNA is important in the therapeutic appli-
cations for a number of diseases [18]. Transcription,
post-transcriptional and post-translational interventions
are the three main time points at which a disease can be
stopped. Before the discovery of antisense RNA most of
the drug targets have been proteins and post-translation
intervention [19]. siRNA is away to control the develop-
ment and progression of diseases earlier on in the pro-
cess. The high specificity of siRNA to target RNA makes
it an important mechanism or tool to find out the func-
t i o no ft h eg e n e[ 2 0 ] .U s eo fR N A ia l o n gw i t h“plasmid
transfection technology with inducible vectors” like
RNA pol III plasmid systems will make it possible to
silence the effects of genes temporarily [19]. The possi-
bility to accomplish RNAi based gene regulation in
transgenic organisms has stimulated many explorations
if this would be a useful option for medical therapy [21].
Results reported from a number of model organisms are
quite promising [22-25] and even in recent clinical trials,
but it is quite early to foretell the outcome of these
challenging efforts.
Longer dsRNAs (50 bp) have a more broad effect in
mammalian somatic cells, resulting in general arrest of
protein synthesis through interferon response and also
protein kinase activation. In contrast, shorter siRNAs of
21-23 nt have a more specific effect, inducing up to 90%
suppression of specific mRNAs both in vitro and in vivo
[26,27]. Due to its high suppression efficiency and
sequence specificity up to a single nucleotide resolution
[28] has encouraged the development of RNAi-based
therapeutic models for possible use in viral infections i.e.
HIV-1 [29], HBV [30], HCV [27], respiratory viruses [31]
and cancer i.e. K-ras [32], PI 3-kinase [33]. The utilization
of short double-strand RNA has completely eliminated
the interferon response and non-specific mRNA degrada-
tion resulting due to long double-strand anti-sense RNA
(>500 nucleotides) in the cytoplasm. Now, short nucleo-
tides are being used for RNAi and have been adapted for
high-throughput use for the transient knockdown of gene
expression in cell lines and animals.
RNAi as a therapeutic agent against HCV
Currently, there is no vaccine available for prevention of
HCV infection due to high degree of strain variation.
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combination with ribavirin is costly, has significant side
effects and fails to cure about half of all infections. HCV
RNA is an attractive target for RNAi, as the single posi-
tive-stranded viral transcript functions both as genomic
RNA and a replication template, and also because of its
localization in the infected liver, an organ that can be
readily targeted by nucleic acid molecules and viral vec-
tors. As Dicer and the RISC act in the cytoplasm so the
cytoplasmic location of RNAi machinery makes it tech-
nically easier than other methods that attempt to silence
genes at the nuclear level. The gene silencing effects of
synthesized siRNA is transient and is typically effective
for approximately 3-7 days before they naturally disap-
pear [34]. So there are little chances of side effects as
with other therapeutic methods such as IFNa and
ribavirin.
Several reports demonstrated potent RNAi activity
against HCV in sub-genomic replicon and fully infec-
tious HCV particles [12]. Synthetic or vector based
siRNAs targeted against 5’ untranslated region (UTR),
HCV core, NS3, NS4B and NS5B were effective in redu-
cing viral replication and infection [4,27,35-37]. The
IRES containing conserved 5’ UTR that is required for
translation, has also been targeted by siRNA. Synthetic
siRNAs and vector-derived shRNA against the 5’ UTR
resulted in 80% inhibition of HCV at a concentration of
2.5 nM [38]. siRNA targeted against 5’ UTR of HCV
sub-genomic replicon with the luciferase gene can also
reduce the level of luciferase activity in a dose-depen-
dent manner up to 85% to 90% [39]. In another report
shRNA targeted to the 5’ UTR inhibited virus replica-
tion and infectivity titers against HCV genotypes 1a and
2a [40]. Moreover, 5’ UTR consensus siRNAs were
designed and showed suppression of HCV genotype-4
replication in vitro in HCV serum infected Huh-7 cells
[41]. shRNAs suppressing the HCV internal ribosomal
entry site (IRES) inhibiting different HCV genotypes
grown in cell culture and replicon replication has also
been reported [42]. While the majority of HCV-siRNAs
Figure 1 How RNAi suppresses genes: Short siRNA pieces unwind into single strand RNAs, which then combine with proteins to form RISC.
The RISC then binds with a native mRNA molecule that complements the short siRNA sequence. If the pairing of native mRNA and siRNA piece
is essentially perfect, the native mRNA is cut into useless RNA fragments that can’t be translated. However, if the nucleotide base pairing is less
than perfect, then the RISC complex binds to the mRNA and prevents the ribosome movement along the mRNA, also halting the translation,
net resulting in no protein tranlation. (http://www.ambion.com/techlib/tn/101/7.html, Last Accessed: 9th April, 2010)
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Page 3 of 6are complementary to the (+) strand, a reduction in
both strands of the viral dsRNA replication intermediate
has been observed [43]. It is plausible that targeting
the (+) strand template indirectly leads to a decrease in
synthesis of (-) strands. Two different groups used
siRNA against Core gene of HCV 1a and 1b genotype
and observed 60% and 80% reduction in mRNA and
protein expression respectively [44,45]. A study demon-
strated that siRNA targeted against E2, NS3 and NS5B
regions effectively inhibit core gene expression [44] and
K i me ta l . ,2 0 0 6 ,h a sd e s i g n e ds i R N Aa g a i n s tH C V1 b
and 1a genome to explore the silencing of structural
genes and showed significantly less expression in a
dose-dependent manner. A fragment of the HCV NS5B
RNA polymerase gene, which was transiently co-trans-
fected with siRNA into mouse liver by hydrodynamic
injection, was reported to be cleaved after treatment
with siRNA [27]. A number of laboratories have shown
that siRNA targeted against protein coding regions of
HCV can inhibit virus replication and expression [4]. It
has been reported that simultaneous transfection with
hairpin ribozymes directed against the 3’UTR HCV
region and SiRNAs targeting the IRES domain triggers
the efficient inhibition (up to 90%) of HCV replication
in subgenomic replicon systems [46]. Although HCV
mouse models are very limited, some groups have
reported RNAi of HCV transgene expression in mice.
One in vivo mouse study reported shRNAs specific to
the HCV 5’UTR were effective at diminishing HCV
internal ribosome entry site (IRES)-driven luciferase
expression [47]. Another study using a similar method
in mice reported silencing of a NS5B-luciferase trans-
gene by NS5B-specific siRNAs [27].
Because dsRNAs can activate the interferon (IFN)
pathway, it was necessary to address whether HCV-spe-
cific siRNAs could trigger IFN production. Kapadia et
al. demonstrated that inhibition of viral replication by
HCV RNAi in vitro was not associated with an up-regu-
lation of IFN-stimulated genes [35]. In fact, HCV siR-
NAs were better at reducing HCV RNA levels than high
doses of IFN-a [35]. An analysis of combined RNAi and
IFN treatment of HCV replicons in cell culture using
lentivirus-delivered shRNAs has been performed and
results indicated that IFN-a enhance gene silencing, and
inhibition of HCV replication [48]. This underscores the
possibility of combination therapies of siRNAs and IFN
against HCV. According to the reports, almost all
regions of HCV show potential for siRNA target with
relative efficiencies of individual siRNA sequences.
Combination therapy of siRNA against host cellular genes
involved in HCV infection
Host genes modulate viral infection and are an impor-
tant target for antiviral therapy against HCV. Besides
targeting HCV replication different studies demon-
strated the feasibility of host cellular factor involved in
infection, as they are not prone to mutations, as poten-
tial targets for siRNA therapy. Many groups have identi-
fied hundreds of host factors utilized by HCV in cell
entry, replication and translation [49-53]. Host proteins
that interact with the structural genes include CD81,
SRBI, Claudin I and occludin [54-56]. CD81 is a tetra-
spanin that promotes HCV entry via its interaction with
HCV E2 and Silencing CD81 with CD81 specific siRNA
has blocked HCV entry in cells [57]. Down-regulation of
Scavenger receptor class B type I (SR-BI) expression by
SR-BI-specific siRNA markedly reduced the susceptibil-
ity of human hepatoma cells to HCV infection [58].
Randall and colleagues in 2003 determined whether
HCV expression is interfered with siRNA against cellu-
lar (Lamin A/C) and viral RNA into Huh-7.5 cells con-
taining replicating HCV. Both viral and cellular RNAs
were efficiently silenced up to 80%. The efficiency of
silencing lamin A/C expression was similar either in
presence or absence of replicating HCV RNAs. Hepatitis
B and C viruses are not cytopathic, but triggers hepatitis
when activate immune cells expressing FasL, infiltrating
the liver, where infection up regulates the death receptor
Fas on hepatocytes, making them major targets for
immune cells and might provide an effective immune
modulating therapy to avoid chronic liver cell damage
[59]. The administration of siRNA and shRNA to target
cellular factor caspase 8, and NS5b has resulted in the
destruction of cognate mRNA and protection of mice
from liver failure [60].
Identification of cellular proteins with enzymatic func-
tions is ideal for development of novel, small molecule
inhibitors and/or therapeutic siRNAs. Two such candi-
dates are ubiquitin specific peptidase 18 (USP18) and
phosphatidylinositol 4-kinase III alpha (PI4K-IIIa). siR-
NAs targeting USP18 have been shown to potentiate the
ability of IFN-a to inhibit HCV replication and virus
production [Randall, 2006]. PI4K-IIIa siRNAs dramati-
cally reduce HCV replication suggesting this is a critical
viral replication cofactor [51-53]. Hsp90 is an important
host derived factor that regulates HCV replication,
siRNA against it inhibits the HCV replication in repli-
con cells and humanized mice liver [61].
HCV and triglyceride rich very low-density lipopro-
teins (VLDLs) both are secreted uniquely by hepatocytes
in the form of membrane vesicles, highly enriched in
proteins required for VLDL assembly, including apolipo-
protein B (apoB), apoE, and microsomal triglyceride
transfer protein, and circulate in blood in a complex.
HCV production was reduced in hepatoma using an
inhibitor of microsomal triglyceride transfer protein and
siRNA directed against apoB indicating the possible
explanation for the restriction of HCV production to
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of HCV infection [62]. Several siRNAs targeted against
human VAMP-associated protein (hVAP-A), La antigen
and polypyrimidine tract binding protein (PTB) mark-
edly decreased the expression levels of corresponding
cellular genes that inhibited HCV replication in Huh-7
cells showing no impact upon cell viability [63]. Combi-
nations of siRNAs directed against cellular HCV cofac-
tors and HCV itself have revealed additive HCV RNA
inhibition effects. Targeting multiple sites of the HCV
genome and host factors involved in HCV replication
are a realistic and valid approach aimed at preventing
the virus from developing resistance.
Conclusion
HCV causes acute and chronic hepatitis which even-
tually lead to permanent liver damage hepatocellular
carcinoma and death. Current therapy for HCV infec-
tion is mainly the combination use of interferon and
ribavirin, but only about half of the treated patients
obtain a sustained antiviral response. Hence, the devel-
opment of new therapies for HCV infection is urgent.
Inhibitory properties of siRNAs on several components
of HCV life cycle have provided a new approach for
antiviral therapy. In the present review, we focused that
combination of siRNA against virus and host genes will
be better option to treat HCV
Abbreviations
HCV: Hepatitis C virus; siRNA: Small interference RNA.
Acknowledgements
Financial support by Higher Education Commission Pakistan is highly
acknowledged.
Author details
1Division of Molecular Medicine, National Centre of Excellence in Molecular
Biology, University of the Punjab, Lahore, Pakistan.
2Institute of Biochemistry
and Biotechnology, University of Veterinary and Animal Sciences, Lahore,
Pakistan.
3Applied and Functional Genomics Lab, Centre of Excellence in
Molecular Biology University of the Punjab, Lahore, Pakistan.
Authors’ contributions
UAA design the study and write up the manuscript. MZY, MA, RE, SJ and OU
helped me in manuscript write up. All the authors read and approved the
final manuscript.
Authors’ information
Usman A Ashfaq (PhD Molecular Biology), Muhammad Z Yousaf (PhD
Molecular Biology), Maida Aslam (Mphil Chemistry), Rahat Ejaz (MSc
microbiology) and Shah Jahan (PhD Molecular Biology)
Competing interests
The authors declare that they have no competing interests.
Received: 28 December 2010 Accepted: 6 June 2011
Published: 6 June 2011
References
1. Raja NS, Janjua KA: Epidemiology of hepatitis C virus infection in Pakistan.
J Microbiol Immunol Infect. J Microbiol Immunol Infect 2008, 41:4-8.
2. Berenguer M, Lopez-Labrador FX, Wright TL: Hepatitis C and liver
transplantation. J Hepatol 2001, 35:666-678.
3. WHO: World Health Organization. Department of Measurement and
Health Information. 2004 [http://www.who.int/healthinfo/statistics/
bodgbddeathdalyestimates.xls].
4. Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue-Gervais IG, Arya S,
Sarangi F, Harris-Brandts M, Beaulieu S, Richardson CD: RNA interference
blocks gene expression and RNA synthesis from hepatitis C replicons
propagated in human liver cells. Proc Natl Acad Sci USA 2003,
100:2783-2788.
5. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G: Approaching
a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine
protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res
2003, 58:1-16.
6. McOmish F, Yap PL, Dow BC: Geographical distribution of hepatitis C
virus genotypes in blood donors: an international collaborative survey.
J Clin Microbiol 1994, 32:884-892.
7. Nousbaum JB, Pol S, Nalpas B, Group atCS: Hepatitis C virus type 1b (II)
infection in France and Italy. Ann Intern Med 1995, 122:161-168.
8. Idrees M, Riazuddin S: Frequency distribution of hepatitis C virus
genotypes in different geographical regions of Pakistan and their
possible routes of transmission. BMC Infect Dis 2008, 8:69.
9. Flamm SL: Chronic hepatitis C virus infection. Jama 2003, 289:2413-2417.
10. Cornberg M, Wedemeyer H, Manns MP: Treatment of chronic hepatitis C
with PEGylated interferon and ribavirin. Curr Gastroenterol Rep 2002,
4:23-30.
11. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D,
Flannery B, Walters K, Dusheiko GM: Ribavirin and interferon alfa-2b in
chronic hepatitis C: assessment of possible pharmacokinetic and
pharmacodynamic interactions. Br J Clin Pharmacol 1998, 46:563-570.
12. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S,
Landthaler M, Landgraf P, Kan S, Lindenbach BD, et al: Cellular cofactors
affecting hepatitis C virus infection and replication. Proc Natl Acad Sci
USA 2007, 104:12884-12889.
13. Hannon GJ: RNA interference. Nature 2002, 418:244-251.
14. Sharp PA: RNA interference–2001. Genes Dev 2001, 15:485-490.
15. Fire A: RNA-triggered gene silencing. Trends Genet 1999, 15:358-363.
16. Szweykowska-Kulinska Z, Jarmolowski A, Figlerowicz M: RNA interference
and its role in the regulation of eucaryotic gene expression. Acta Biochim
Pol 2003, 50:217-229.
17. Meister G, Tuschl T: Mechanisms of gene silencing by double-stranded
RNA. Nature 2004, 343-349.
18. Ullu E, Tschudi C: RNAi-applications in parasitology. New technologies for
life sciences. A Trends Guide 2000 2000, 43-46.
19. Shuey DJ, McCallus DE, Giordano T: RNAi: gene-silencing in therapeutic
intervention. Drug Discov Today 2002, 7:1040-1046.
20. Tuschl T: RNA interference and small interfering RNAs. Chembiochem
2001, 2:239-245.
21. Hannon GJ, Rossi JJ: Unlocking the potential of the human genome with
RNA interference. Nature 2004, 431:371-378.
22. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M,
Elbashir S, Geick A, Hadwiger P, Harborth J, et al: Therapeutic silencing of
an endogenous gene by systemic administration of modified siRNAs.
Nature 2004, 432:173-178.
23. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W,
Hartsough K, Machemer L, Radka S, Jadhav V, et al: Potent and persistent
in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol
2005, 23:1002-1007.
24. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM,
Lieberman J: An siRNA-based microbicide protects mice from lethal
herpes simplex virus 2 infection. Nature 2006, 439:89-94.
25. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN,
Harborth J, Heyes JA, Jeffs LB, John M, et al: RNAi-mediated gene silencing
in non-human primates. Nature 2006, 441:111-114.
26. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes
of 21-nucleotide RNAs mediate RNA interference in cultured mammalian
cells. Nature 2001, 411:494-498.
27. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA: RNA
interference in adult mice. Nature 2002, 418:38-39.
28. Elbashir SM, Lendeckel W, Tuschl T: RNA interference is mediated by 21-
and 22-nucleotide RNAs. Genes Dev 2001, 15:188-200.
Ashfaq et al. Virology Journal 2011, 8:276
http://www.virologyj.com/content/8/1/276
Page 5 of 629. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J:
Expression of small interfering RNAs targeted against HIV-1 rev
transcripts in human cells. Nat Biotechnol 2002, 20:500-505.
30. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF,
Marion PL, Kay MA: Inhibition of hepatitis B virus in mice by RNA
interference. Nat Biotechnol 2003, 21:639-644.
31. Bitko V, Musiyenko A, Shulyayeva O, Barik S: Inhibition of respiratory
viruses by nasally administered siRNA. Nat Med 2005, 11:50-55.
32. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of
short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
33. Caplen NJ: Gene therapy progress and prospects. Downregulating gene
expression: the impact of RNA interference. Gene Ther 2004, 11:1241-1248.
34. Saito Y, Dzik S: Gene knockdown: RNA-interference is coming of age.
Transfusion 2005, 45:111-114.
35. Kapadia SB, Brideau-Andersen A, Chisari FV: Interference of hepatitis C
virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA
2003, 100:2014-2018.
36. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, Heathcote J,
Rice CM, Edwards AM, McGilvray ID: Silencing of USP18 potentiates the
antiviral activity of interferon against hepatitis C virus infection.
Gastroenterology 2006, 131:1584-1591.
37. Takigawa Y, Nagano-Fujii M, Deng L, Hidajat R, Tanaka M, Mizuta H,
Hotta H: Suppression of hepatitis C virus replicon by RNA interference
directed against the NS3 and NS5B regions of the viral genome.
Microbiol Immunol 2004, 48:591-598.
38. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L,
Kurosaki M, Taira K, Watanabe M, Mizusawa H: Inhibition of intracellular
hepatitis C virus replication by synthetic and vector-derived small
interfering RNAs. EMBO Rep 2003, 4:602-608.
39. Seo MY, Abrignani S, Houghton M, Han JH: Small interfering RNA-
mediated inhibition of hepatitis C virus replication in the human
hepatoma cell line Huh-7. J Virol 2003, 77:810-812.
40. Kanda T, Steele R, Ray R, Ray RB: Small interfering RNA targeted to
hepatitis C virus 5’ nontranslated region exerts potent antiviral effect.
J Virol 2007, 81:669-676.
41. Zekri AR, Bahnassy AA, El-Din HM, Salama HM: Consensus siRNA for
inhibition of HCV genotype-4 replication. Virol J 2009, 6:13.
42. Ray RB, Kanda T: Inhibition of HCV replication by small interfering RNA.
Methods Mol Biol 2009, 510:251-262.
43. Wilson JA, Richardson CD: Hepatitis C virus replicons escape RNA
interference induced by a short interfering RNA directed against the
NS5b coding region. J Virol 2005, 79:7050-7058.
44. Liu M, Ding H, Zhao P, Qin ZL, Gao J, Cao MM, Luan J, Wu WB, Qi ZT: RNA
interference effectively inhibits mRNA accumulation and protein
expression of hepatitis C virus core and E2 genes in human cells. Biosci
Biotechnol Biochem 2006, 70:2049-2055.
45. Kim M, Shin D, Kim SI, Park M: Inhibition of hepatitis C virus gene
expression by small interfering RNAs using a tri-cistronic full-length viral
replicon and a transient mouse model. Virus Res 2006, 122:1-10.
46. Jarczak D, Korf M, Beger C, Manns MP, Kruger M: Hairpin ribozymes in
combination with siRNAs against highly conserved hepatitis C virus
sequence inhibit RNA replication and protein translation from hepatitis
C virus subgenomic replicons. Febs J 2005, 272:5910-5922.
47. Wang Q, Contag CH, Ilves H, Johnston BH, Kaspar RL: Small hairpin RNAs
efficiently inhibit hepatitis C IRES-mediated gene expression in human
tissue culture cells and a mouse model. Mol Ther 2005, 12:562-568.
48. Pan Q, Henry SD, Metselaar HJ, Scholte B, Kwekkeboom J, Tilanus HW,
Janssen HL, van der Laan LJ: Combined antiviral activity of interferon-
alpha and RNA interference directed against hepatitis C without
affecting vector delivery and gene silencing. J Mol Med 2009, 87:713-722.
49. Ng TI, Mo H, Pilot-Matias T, He Y, Koev G, Krishnan P, Mondal R,
Pithawalla R, He W, Dekhtyar T, et al: Identification of host genes involved
in hepatitis C virus replication by small interfering RNA technology.
Hepatology 2007, 45:1413-1421.
50. Supekova L, Supek F, Lee J, Chen S, Gray N, Pezacki JP, Schlapbach A,
Schultz PG: Identification of human kinases involved in hepatitis C virus
replication by small interference RNA library screening. J Biol Chem 2008,
283:29-36.
51. Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G,
Grakoui A, Randall G: Roles for endocytic trafficking and
phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication.
Proc Natl Acad Sci USA 2009, 106:7577-7582.
52. Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, Chung RT: A
functional genomic screen identifies cellular cofactors of hepatitis C
virus replication. Cell Host Microbe 2009, 5:298-307.
53. Vaillancourt FH, Pilote L, Cartier M, Lippens J, Liuzzi M, Bethell RC,
Cordingley MG, Kukolj G: Identification of a lipid kinase as a host factor
involved in hepatitis C virus RNA replication. Virology 2009, 387:5-10.
54. Barth H, Liang TJ, Baumert TF: Hepatitis C virus entry: molecular biology
and clinical implications. Hepatology 2006, 44:527-535.
55. Bartosch B, Cosset FL: Cell entry of hepatitis C virus. Virology 2006,
348:1-12.
56. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B,
Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM: Claudin-1 is a
hepatitis C virus co-receptor required for a late step in entry. Nature
2007, 446:801-805.
57. Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA: CD81
is required for hepatitis C virus glycoprotein-mediated viral infection.
J Virol 2004, 78:1448-1455.
58. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL,
Wakita T, Jaeck D, Doffoel M, Royer C, et al: Scavenger receptor class B
type I is a key host factor for hepatitis C virus infection required for an
entry step closely linked to CD81. Hepatology 2007, 46:1722-1731.
59. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P,
Lieberman J: RNA interference targeting Fas protects mice from
fulminant hepatitis. Nat Med 2003, 9:347-351.
60. Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B,
Waltemathe M, Gosling T, Flemming P, Malek NP, et al: Caspase 8 small
interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci
USA 2003, 100:7797-7802.
61. Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M: Hsp90
inhibitors suppress HCV replication in replicon cells and humanized liver
mice. Biochem Biophys Res Commun 2007, 353:882-888.
62. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M Jr, Ye J: Hepatitis C virus
production by human hepatocytes dependent on assembly and
secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007,
104:5848-5853.
63. Xue Q, Ding H, Liu M, Zhao P, Gao J, Ren H, Liu Y, Qi ZT: Inhibition of
hepatitis C virus replication and expression by small interfering RNA
targeting host cellular genes. Arch Virol 2007, 152:955-962.
doi:10.1186/1743-422X-8-276
Cite this article as: Ashfaq et al.: siRNAs: Potential therapeutic agents
against Hepatitis C Virus. Virology Journal 2011 8:276.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ashfaq et al. Virology Journal 2011, 8:276
http://www.virologyj.com/content/8/1/276
Page 6 of 6